| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514900300 | Fibronectin or derivative | 18 |
| 20110034384 | COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS - The present disclosure relates to improved methods of treating neoplastic disorders by combining VEGFR2 specific inhibitor treatment with mTOR inhibitors. The present disclosure also relates to methods of preventing the development of VEGFR2 resistance. | 02-10-2011 |
| 20110053842 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR - The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 03-03-2011 |
| 20110071079 | SELF-ASSEMBLING POLY(DIOL CITRATES)-PROTEIN HYDROGELS - The present invention can be directed to poly(diol-citrate)-based copolymers, compositions thereof comprising protein components and methods of use and assembly. | 03-24-2011 |
| 20120094909 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO PCSK9 - The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein. | 04-19-2012 |
| 20120220523 | USE OF A CORN PEPTIDI HYDROLYZATE AS AN ACTIVE AGENT STIMULATING HAIR GROWTH - The invention relates to the use of a composition comprising at least one corn ( | 08-30-2012 |
| 20130012436 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND IL-23 - The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23), specifically the p19 subunit of IL-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 01-10-2013 |
| 20130079280 | FIBRONECTIN TYPE III DOMAIN-BASED MULTIMERIC SCAFFOLDS - The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds. | 03-28-2013 |
| 20130096058 | TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS - The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer. | 04-18-2013 |
| 20130157948 | BISPECIFIC EGFR/IGFIR BINDING MOLECULES - The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain. | 06-20-2013 |
| 20130184212 | FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY - The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides. | 07-18-2013 |
| 20130217625 | COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS - Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10 | 08-22-2013 |
| 20140038893 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR - The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 02-06-2014 |
| 20140187488 | METHODS FOR MAINTAINING PEGYLATION OF POLYPEPTIDES - Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage. | 07-03-2014 |
| 20150051149 | FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY - Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity. | 02-19-2015 |
| 20160152686 | FIBRONECTIN BASED SCAFFOLD DOMAINS LINKED TO SERUM ALBUMIN OR MOIETY BINDING THERETO | 06-02-2016 |
| 20160152688 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR | 06-02-2016 |
| 20160159883 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9 - The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein. | 06-09-2016 |
| 20160376345 | FIBRONECTIN-BASED BINDING MOLECULES AND USES THEREOF - The invention provides fibronectin type III (Fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific Fn3-based binding molecules that bind to two or more targets simultaneously. The Fn3-based binding molecules of the invention can also be linked together to form multispecific Fn3-based binding molecules, and/or can be conjugated to a non-Fn3 moiety, such as, Human Serum Albumin (HSA), for improved half life and stability. The invention also provides methods for generating, screening and using Fn3-based binding molecules in a variety of therapeutic and diagnostic applications. | 12-29-2016 |
